Karyopharm Therapeutics Stock Intrinsic Value – Karyopharm Therapeutics Plunges 1.56% on Tuesday, 03/07/23, Closing at $3.15 in 2023.
March 11, 2023
Trending News 🌥️
Karyopharm Therapeutics ($NASDAQ:KPTI) Inc. experienced a sharp decline on Tuesday, 03/07/23, closing at $3.15 – a decrease of 1.56% from its previous closing price. Investors were left wondering what caused the sudden dip in the company’s stock price. The company specialized in the development of treatments for various types of cancer and other diseases, and had recently announced promising clinical results on its lead drug selinexor, which is being studied as a potential treatment for multiple myeloma. Despite these positive developments, the stock market responded negatively and Karyopharm shares closed the session at $3.15. This decline surprised many investors, as Karyopharm was considered one of the strongest companies in its sector, with a number of promising drugs in various stages of development. Overall, it is difficult to pinpoint the exact cause of the decline in Karyopharm share prices on Tuesday, 03/07/23.
However, it is clear that investors remain concerned about the company’s future prospects and it is important for Karyopharm to work hard to regain investor confidence in light of these recent events.
Market Price
The company opened at $3.1 and dropped by 5.1% from the previous closing price of $3.1. This significant drop in price may be linked to the broader market downturn seen across many stocks, as investors are cautious of the economic aftermath of the pandemic. The plunge follows an overall downward trend for the stock over the past few months. Despite the company’s efforts to remain resilient, the effects of the pandemic have had a negative impact on its share value.
Investors are concerned about the financial uncertainty of the industry, which is likely to be reflected in Karyopharm’s stock performance. It remains to be seen what the future holds for the company and its investors, but it is clear that the impact of the pandemic is still being felt in the stock market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 157.07 | -165.29 | -105.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…
| Operations | Investing | Financing |
| -97.24 | 141.84 | 73.65 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 358.17 | 374.83 | -1.24 |
Key Ratios Snapshot
Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 56.6% | – | -89.1% |
| FCF Margin | ROE | ROA |
| -61.8% | 62.3% | -24.4% |
Analysis – Karyopharm Therapeutics Stock Intrinsic Value
At GoodWhale, we have conducted a thorough analysis of KARYOPHARM THERAPEUTICS‘s financials. After carefully reviewing the financial data, our proprietary Valuation Line has estimated KARYOPHARM THERAPEUTICS’s fair value share to be around $8.9. Currently, KARYOPHARM THERAPEUTICS stock is traded at $3.0, meaning it is undervalued by a whopping 66.2%. More…
Peers
The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.
– Neovacs SA ($LTS:0W8U)
Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.
Summary
Karyopharm Therapeutics Inc. saw a significant drop in stock price on Tuesday, 03/07/23, closing at $3.15. This represents a 1.56% decrease in price for the day. For investors, this type of movement can be a sign of a long-term trend or a one-time change. It is important to analyze the company’s financials, news, and other indicators to better understand what is driving the price movements. Karyopharm Therapeutics Inc. specializes in the development of novel treatments for cancer and other serious diseases, and any changes in their progress could affect the stock price.
Additionally, changes in competitive landscape and potential partnerships could also play a role in stock movements. Investors should monitor these indicators to stay informed and make strategic decisions.
